Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) has been assigned an average rating of “Buy” from the twenty-eight research firms that are presently covering the firm. Eleven investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $117.63.

A number of research analysts recently weighed in on the stock. Jefferies Group reiterated a “buy” rating and issued a $107.00 price objective (up from $102.00) on shares of Vertex Pharmaceuticals in a research note on Sunday, July 31st. Vetr upgraded shares of Vertex Pharmaceuticals from a “buy” rating to a “strong-buy” rating and set a $94.50 price objective for the company in a research note on Monday, June 27th. Morgan Stanley reduced their price objective on shares of Vertex Pharmaceuticals from $140.00 to $139.00 and set an “overweight” rating for the company in a research note on Thursday, July 28th. JMP Securities reiterated a “buy” rating on shares of Vertex Pharmaceuticals in a research note on Tuesday, August 16th. Finally, Piper Jaffray Cos. reiterated a “buy” rating on shares of Vertex Pharmaceuticals in a research note on Saturday, June 18th.

Vertex Pharmaceuticals (NASDAQ:VRTX) traded up 0.69% during midday trading on Tuesday, reaching $91.89. The company’s stock had a trading volume of 494,213 shares. Vertex Pharmaceuticals has a 12 month low of $75.90 and a 12 month high of $134.71. The stock has a 50-day moving average price of $97.70 and a 200 day moving average price of $89.49. The company’s market cap is $22.77 billion.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/vertex-pharmaceuticals-inc-nasdaqvrtx-receives-consensus-rating-of-buy-from-brokerages.html

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Wednesday, July 27th. The pharmaceutical company reported $0.24 EPS for the quarter, topping analysts’ consensus estimates of $0.21 by $0.03. The company had revenue of $431.61 million for the quarter, compared to analysts’ expectations of $428.08 million. Vertex Pharmaceuticals had a negative net margin of 17.77% and a negative return on equity of 12.34%. Vertex Pharmaceuticals’s revenue was up 159.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.54) EPS. Analysts expect that Vertex Pharmaceuticals will post $1.00 earnings per share for the current fiscal year.

In other Vertex Pharmaceuticals news, Director Joshua S. Boger sold 5,130 shares of the company’s stock in a transaction dated Wednesday, June 22nd. The shares were sold at an average price of $86.61, for a total value of $444,309.30. Following the sale, the director now owns 273,355 shares in the company, valued at $23,675,276.55. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Joshua S. Boger sold 6,500 shares of the company’s stock in a transaction dated Wednesday, July 13th. The stock was sold at an average price of $88.81, for a total transaction of $577,265.00. Following the completion of the sale, the director now owns 274,725 shares in the company, valued at approximately $24,398,327.25. The disclosure for this sale can be found here. Corporate insiders own 1.90% of the company’s stock.

A number of large investors have recently made changes to their positions in VRTX. Citizens Financial Group Inc RI boosted its stake in shares of Vertex Pharmaceuticals by 27.0% in the second quarter. Citizens Financial Group Inc RI now owns 1,189 shares of the pharmaceutical company’s stock worth $102,000 after buying an additional 253 shares during the period. Mycio Wealth Partners LLC boosted its stake in shares of Vertex Pharmaceuticals by 1.5% in the second quarter. Mycio Wealth Partners LLC now owns 1,218 shares of the pharmaceutical company’s stock worth $105,000 after buying an additional 18 shares during the period. Paradigm Asset Management Co. LLC boosted its stake in shares of Vertex Pharmaceuticals by 20.7% in the second quarter. Paradigm Asset Management Co. LLC now owns 1,450 shares of the pharmaceutical company’s stock worth $125,000 after buying an additional 249 shares during the period. BlueMountain Capital Management LLC boosted its stake in shares of Vertex Pharmaceuticals by 69.3% in the first quarter. BlueMountain Capital Management LLC now owns 1,867 shares of the pharmaceutical company’s stock worth $148,000 after buying an additional 764 shares during the period. Finally, Checchi Capital Advisers LLC boosted its stake in shares of Vertex Pharmaceuticals by 4.3% in the second quarter. Checchi Capital Advisers LLC now owns 1,763 shares of the pharmaceutical company’s stock worth $152,000 after buying an additional 73 shares during the period. Institutional investors and hedge funds own 96.26% of the company’s stock.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated is engaged in the business of discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company operates in pharmaceuticals segment. Its business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

5 Day Chart for NASDAQ:VRTX

Receive News & Ratings for Vertex Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.